

# Humira Market Size, Share & Trends Analysis Report By Product (Branded, Biosimilar), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/H8B0C7734715EN.html

Date: May 2025

Pages: 100

Price: US\$ 5,950.00 (Single User License)

ID: H8B0C7734715EN

# **Abstracts**

This report can be delivered to the clients within 2 Business Days

**Humira Market Growth & Trends** 

The global humira market size is projected to reach USD 4.11 billion by 2030, declining at a CAGR of -11.29% during the forecast period, according to a new report by Grand View Research, Inc. Despite this decline, the market continues to experience sustained demand, driven by the rising global prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Humira has long been a cornerstone of treatment for these conditions, and demand for effective biologic therapies remains strong. However, as the market shifts, the entry of biosimilars and evolving regulatory frameworks are reshaping its dynamics.

The decline in Humira's market share is largely attributed to the growing availability of biosimilars. With the expiration of key patents, biosimilars, driven by regulatory support and cost-containment strategies, are becoming increasingly accessible, particularly in emerging markets. As a result, there is a shift towards more affordable alternatives, increasing the adoption of biosimilars and expanding patient access. Although Humira's proven efficacy continues to make it a top choice for managing autoimmune diseases, the increasing presence of biosimilars leads to a competitive pricing environment and reduces its overall market dominance.



Despite the market's decline, significant growth opportunities remain, especially in developing regions where healthcare infrastructure is improving and awareness of autoimmune conditions is rising. The expanding indications for Humira and new formulations, such as citrate-free versions and high-concentration injectables, drive continued demand for the drug, particularly in regions with a strong healthcare framework and reimbursement support.

Pharmaceutical companies, including AbbVie and leading biosimilar manufacturers like Amgen, Sandoz, and Teva, are navigating the evolving landscape through strategic partnerships, product differentiation, and lifecycle management. AbbVie has retained significant market share through brand loyalty, extensive clinical data, and physician trust, despite the emergence of biosimilars in 2024.

Recent developments, such as the launch of interchangeable biosimilars like Simlandi and initiatives like Evernorth's zero out-of-pocket cost program, highlight the growing push for affordable access. As biosimilars rapidly gain approval and expand market presence, the competitive landscape of the Humira industry is becoming increasingly dynamic. The market is expected to continue evolving, with key players focusing on expanding indications, enhancing delivery systems, and penetrating underserved regions to capitalize on the shifting dynamics of autoimmune disease treatment.

# **Humira Market Report Highlights**

Based on product, Branded Humira dominated the market, accounting for 87.0% of the share in 2024. This dominance is attributed to its proven clinical efficacy, wide-ranging regulatory approvals across multiple autoimmune conditions, and long-standing physician and patient trust in the brand.

Based on application, rheumatoid arthritis dominated the market and accounted for a share of 20.5% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.

Based on distribution channel, hospital Pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the growing demand for biologic therapies used in managing autoimmune conditions. Humira is a preferred treatment option prescribed and dispensed through hospital settings for patients requiring specialized care.

Key players in the market include AbbVie, Amgen, Boehringer Ingelheim, Pfizer,



Samsung Bioepis, and Sandoz. Competition is intensifying with the growing presence of biosimilar manufacturers, especially following the expiration of Humira's key patents, which has opened the market to a broader range of adalimumab-based therapies.

In June 2024, Coherus BioSciences revealed it had completed the sale of its Humira biosimilar, YUSIMRY, to Hong Kong King-Friend Industrial Co. Ltd. for USD 40 million in cash, with the transaction closing on June 26, 2024. YUSIMRY will continue to be commercialized in the U.S. by Meitheal Pharmaceuticals, a subsidiary of HKF. Coherus noted that the divestiture aligns with its strategic focus on advancing its oncology portfolio.

# **Companies Mentioned**

Alvotech

Amgen Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

CELLTRION INC.

Coherus BioSciences, Inc.

Fresenius Kabi AG

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.

Pfizer Inc.

Samsung Bioepis

Sandoz Inc.



# **Contents**

#### **CHAPTER 1. METHODOLOGY AND SCOPE**

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
  - 1.2.1. Product
  - 1.2.2. Application
  - 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
  - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

## **CHAPTER 2. EXECUTIVE SUMMARY**

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

#### CHAPTER 3. HUMIRA MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
  - 3.2.1. Market Driver Analysis
  - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power



- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis

#### **CHAPTER 4. HUMIRA MARKET: PRODUCT BUSINESS ANALYSIS**

- 4.1. Product Market Share, 2024 & 2030
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Branded
  - 4.4.1. Branded Market, 2018 2030 (USD Million)
- 4.5. Biosimilar
  - 4.5.1. Biosimilar Market, 2018 2030 (USD Million)

#### CHAPTER 5. HUMIRA MARKET: APPLICATION BUSINESS ANALYSIS

- 5.1. Application Market Share, 2024 & 2030
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Rheumatoid Arthritis
  - 5.4.1. Rheumatoid Arthritis Market, 2018 2030 (USD Million)
- 5.5. Psoriatic Arthritis
  - 5.5.1. Psoriatic Arthritis Market, 2018 2030 (USD Million)
- 5.6. Crohn's Disease
  - 5.6.1. Crohn's Disease Market, 2018 2030 (USD Million)
- 5.7. Ulcerative Colitis
  - 5.7.1. Ulcerative Colitis Market, 2018 2030 (USD Million)
- 5.8. Ankylosing Spondylitis
  - 5.8.1. Ankylosing Spondylitis Market, 2018 2030 (USD Million)
- 5.9. Others
  - 5.9.1. Others Market, 2018 2030 (USD Million)



#### **CHAPTER 6. HUMIRA MARKET: DISTRIBUTION CHANNEL BUSINESS ANALYSIS**

- 6.1. Distribution Channel Market Share, 2024 & 2030
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
- 6.4. Hospital Pharmacies
  - 6.4.1. Hospital Pharmacies Market, 2018 2030 (USD Million)
- 6.5. Retail Pharmacies
  - 6.5.1. Retail Pharmacies Market, 2018 2030 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2018 2030 (USD Million)

#### CHAPTER 7. HUMIRA MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America Humira Market Estimates And Forecasts, By Country, 2018 2030 (USD Million)
  - 7.4.2. U.S.
    - 7.4.2.1. Key Country Dynamics
    - 7.4.2.2. Target Disease Prevalence
    - 7.4.2.3. Regulatory Framework
    - 7.4.2.4. Reimbursement Framework
    - 7.4.2.5. U.S. Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Target Disease Prevalence
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Reimbursement Framework
  - 7.4.3.5. U.S. Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Target Disease Prevalence
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Reimbursement Framework
  - 7.4.4.5. Mexico Humira Market Estimates and Forecasts, 2018 2030 (USD Million)



### 7.5. Europe

- 7.5.1. Europe Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Target Disease Prevalence
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Reimbursement Framework
  - 7.5.2.5. Uk Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Target Disease Prevalence
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Humira Market Estimates and Forecasts, 2018 2030 (USD

# Million)

- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Target Disease Prevalence
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. Reimbursement Framework
  - 7.5.4.5. France Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Target Disease Prevalence
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Reimbursement Framework
  - 7.5.5.5. Italy Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Target Disease Prevalence
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Reimbursement Framework
  - 7.5.6.5. Spain Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Humira Market Estimates and Forecasts, 2018 2030 (USD Million)



- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Target Disease Prevalence
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Reimbursement Framework
  - 7.5.8.5. Sweden Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Target Disease Prevalence
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Reimbursement Framework
  - 7.5.9.5. Norway Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.6. Asia Pacific
  - 7.6.1. Asia Pacific Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.6.2. Japan
    - 7.6.2.1. Key Country Dynamics
    - 7.6.2.2. Target Disease Prevalence
    - 7.6.2.3. Regulatory Framework
    - 7.6.2.4. Reimbursement Framework
    - 7.6.2.5. Japan Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Framework
  - 7.6.3.5. China Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.6.4. India
    - 7.6.4.1. Key Country Dynamics
    - 7.6.4.2. Target Disease Prevalence
    - 7.6.4.3. Regulatory Framework
    - 7.6.4.4. Reimbursement Framework
    - 7.6.4.5. India Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.6.5. Australia
    - 7.6.5.1. Key Country Dynamics
    - 7.6.5.2. Target Disease Prevalence
    - 7.6.5.3. Regulatory Framework
    - 7.6.5.4. Reimbursement Framework
    - 7.6.5.5. Australia Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.6.6. South Korea



- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.6.7. Thailand
    - 7.6.7.1. Key Country Dynamics
    - 7.6.7.2. Target Disease Prevalence
    - 7.6.7.3. Regulatory Framework
    - 7.6.7.4. Reimbursement Framework
    - 7.6.7.5. Thailand Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.7.2. Brazil
    - 7.7.2.1. Key Country Dynamics
    - 7.7.2.2. Target Disease Prevalence
    - 7.7.2.3. Regulatory Framework
    - 7.7.2.4. Reimbursement Framework
    - 7.7.2.5. Japan Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.7.3. Argentina
    - 7.7.3.1. Key Country Dynamics
    - 7.7.3.2. Target Disease Prevalence
    - 7.7.3.3. Regulatory Framework
    - 7.7.3.4. Reimbursement Framework
    - 7.7.3.5. China Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Humira Market Estimates and Forecasts, 2017 2030 (USD Million)
  - 7.8.2. South Africa
    - 7.8.2.1. Key Country Dynamics
    - 7.8.2.2. Target Disease Prevalence
    - 7.8.2.3. Regulatory Framework
    - 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics



- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.8.4. UAE
    - 7.8.4.1. Key Country Dynamics
    - 7.8.4.2. Target Disease Prevalence
    - 7.8.4.3. Regulatory Framework
    - 7.8.4.4. Reimbursement Framework
    - 7.8.4.5. UAE Humira Market Estimates and Forecasts, 2018 2030 (USD Million)
  - 7.8.5. Kuwait
    - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Target Disease Prevalence
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Reimbursement Framework
  - 7.8.5.5. Kuwait Humira Market Estimates and Forecasts, 2018 2030 (USD Million)

#### **CHAPTER 8. COMPETITIVE LANDSCAPE**

- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
  - 8.5.1. AbbVie
    - 8.5.1.1. Overview
    - 8.5.1.2. Financial Performance
    - 8.5.1.3. Product Benchmarking
    - 8.5.1.4. Strategic Initiatives
  - 8.5.2. Alvotech
    - 8.5.2.1. Overview
    - 8.5.2.2. Financial Performance
    - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
  - 8.5.3. Amgen Inc.
    - 8.5.3.1. Overview
    - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking



- 8.5.3.4. Strategic Initiatives
- 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Celltrion Inc.
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Coherus Biosciences, Inc
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Fresenius Kabi AG
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Fujiflim Kyowa Kiran Biologics Co., Ltd.
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Pfizer Inc.
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Samsung Bioepis
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives
- 8.5.11. Sandoz Inc.
- 8.5.11.1. Overview
- 8.5.11.2. Financial Performance



8.5.11.3. Product Benchmarking

8.5.11.4. Strategic Initiatives



# **List Of Tables**

#### LIST OF TABLES

- Table 1. List of secondary sources
- Table 2. List of abbreviations
- Table 3. Global Humira market, by region, 2018 2030 (USD Million)
- Table 4. Global Humira market, by product, 2018 2030 (USD Million)
- Table 5. Global Humira market, by application, 2018 2030 (USD Million)
- Table 6. Global Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 7. North America Humira market, by country, 2018 2030 (USD Million)
- Table 8. North America Humira market, by product, 2018 2030 (USD Million)
- Table 9. North America Humira market, by application, 2018 2030 (USD Million)
- Table 10. North America Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 11. U.S. Humira market, by product, 2018 2030 (USD Million)
- Table 12. U.S. Humira market, by application, 2018 2030 (USD Million)
- Table 13. U.S. Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 14. Canada Humira market, by product, 2018 2030 (USD Million)
- Table 15. Canada Humira market, by application, 2018 2030 (USD Million)
- Table 16. Canada Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 17. Mexico Humira market, by product, 2018 2030 (USD Million)
- Table 18. Mexico Humira market, by application, 2018 2030 (USD Million)
- Table 19. Mexico Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 20. Europe Humira market, by country, 2018 2030 (USD Million)
- Table 21. Europe Humira market, by product, 2018 2030 (USD Million)
- Table 22. Europe Humira market, by application, 2018 2030 (USD Million)
- Table 23. Europe Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 24. UK Humira market, by product, 2018 2030 (USD Million)
- Table 25. UK Humira market, by application, 2018 2030 (USD Million)
- Table 26. UK Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 27. Germany Humira market, by product, 2018 2030 (USD Million)
- Table 28. Germany Humira market, by application, 2018 2030 (USD Million)
- Table 29. Germany Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 30. France Humira market, by product, 2018 2030 (USD Million)
- Table 31. France Humira market, by application, 2018 2030 (USD Million)
- Table 32. France Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 33. Italy Humira market, by product, 2018 2030 (USD Million)
- Table 34. Italy Humira market, by application, 2018 2030 (USD Million)



- Table 35. Italy Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 36. Spain Humira market, by product, 2018 2030 (USD Million)
- Table 37. Spain Humira market, by application, 2018 2030 (USD Million)
- Table 38. Spain Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 39. Norway Humira market, by product, 2018 2030 (USD Million)
- Table 40. Norway Humira market, by application, 2018 2030 (USD Million)
- Table 41. Norway Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 42. Denmark Humira market, by product, 2018 2030 (USD Million)
- Table 43. Denmark Humira market, by application, 2018 2030 (USD Million)
- Table 44. Denmark Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 45. Sweden Humira market, by product, 2018 2030 (USD Million)
- Table 46. Sweden Humira market, by application, 2018 2030 (USD Million)
- Table 47. Sweden Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 48. Asia Pacific Humira market, by country, 2018 2030 (USD Million)
- Table 49. Asia Pacific Humira market, by product, 2018 2030 (USD Million)
- Table 50. Asia Pacific Humira market, by application, 2018 2030 (USD Million)
- Table 51. Asia Pacific Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 52. Japan Humira market, by product, 2018 2030 (USD Million)
- Table 53. Japan Humira market, by application, 2018 2030 (USD Million)
- Table 54. Japan Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 55. China Humira market, by product, 2018 2030 (USD Million)
- Table 56. China Humira market, by application, 2018 2030 (USD Million)
- Table 57. China Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 58. India Humira market, by product, 2018 2030 (USD Million)
- Table 59. India Humira market, by application, 2018 2030 (USD Million)
- Table 60. India Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 61. Australia Humira market, by product, 2018 2030 (USD Million)
- Table 62. Australia Humira market, by application, 2018 2030 (USD Million)
- Table 63. Australia Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 64. South Korea Humira market, by product, 2018 2030 (USD Million)
- Table 65. South Korea Humira market, by application, 2018 2030 (USD Million)
- Table 66. South Korea Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 67. Thailand Humira market, by product, 2018 2030 (USD Million)
- Table 68. Thailand Humira market, by application, 2018 2030 (USD Million)
- Table 69. Thailand Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 70. Latin America Humira market, by country, 2018 2030 (USD Million)
- Table 71. Latin America Humira market, by product, 2018 2030 (USD Million)



- Table 72. Latin America Humira market, by application, 2018 2030 (USD Million)
- Table 73. Latin America Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 74. Brazil Humira market, by product, 2018 2030 (USD Million)
- Table 75. Brazil Humira market, by application, 2018 2030 (USD Million)
- Table 76. Brazil Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 77. Argentina Humira market, by product, 2018 2030 (USD Million)
- Table 78. Argentina Humira market, by application, 2018 2030 (USD Million)
- Table 79. Argentina Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 80. Middle East & Africa Humira market, by country, 2018 2030 (USD Million)
- Table 81. Middle East & Africa Humira market, by product, 2018 2030 (USD Million)
- Table 82. Middle East & Africa Humira market, by application, 2018 2030 (USD Million)
- Table 83. Middle East & Africa Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 84. South Africa Humira market, by product, 2018 2030 (USD Million)
- Table 85. South Africa Humira market, by application, 2018 2030 (USD Million)
- Table 86. South Africa Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 87. Saudi Arabia Humira market, by product, 2018 2030 (USD Million)
- Table 88. Saudi Arabia Humira market, by application, 2018 2030 (USD Million)
- Table 89. Saudi Arabia Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 90. UAE Humira market, by product, 2018 2030 (USD Million)
- Table 91. UAE Humira market, by application, 2018 2030 (USD Million)
- Table 92. UAE Humira market, by distribution channel, 2018 2030 (USD Million)
- Table 93. Kuwait Humira market, by product, 2018 2030 (USD Million)
- Table 94. Kuwait Humira market, by application, 2018 2030 (USD Million)
- Table 95. Kuwait Humira market, by distribution channel, 2018 2030 (USD Million)



# **List Of Figures**

#### LIST OF FIGURES

- Fig. 1 Humira market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Therapeutic approach and application outlook (USD Million)
- Fig. 10 Competitive landscape
- Fig. 11 Humira market dynamics
- Fig. 12 Humira market: Porter's five forces analysis
- Fig. 13 Humira market: PESTLE analysis
- Fig. 14 Product market, 2018 2030 (USD Million)
- Fig. 15 Branded market, 2018 2030 (USD Million)
- Fig. 16 Biosimilar market, 2018 2030 (USD Million)
- Fig. 17 Application market, 2018 2030 (USD Million)
- Fig. 18 Rheumatoid Arthritis market, 2018 2030 (USD Million)
- Fig. 19 Psoriatic Arthritis market, 2018 2030 (USD Million)
- Fig. 20 Crohn's Diseases market, 2018 2030 (USD Million)
- Fig. 21 Ulcerative Colitis market, 2018 2030 (USD Million)
- Fig. 22 Ankylosing Spondylitis market, 2018 2030 (USD Million)
- Fig. 23 Others market, 2018 2030 (USD Million)
- Fig. 24 Distribution Channel market, 2018 2030 (USD Million)
- Fig. 25 Hospital Pharmacies market, 2018 2030 (USD Million)
- Fig. 26 Retail Pharmacies market, 2018 2030 (USD Million)
- Fig. 27 Online Pharmacies market, 2018 2030 (USD Million)
- Fig. 28 Humira market revenue, by region
- Fig. 29 Regional marketplace: Key takeaways
- Fig. 30 Regional marketplace: Key takeaways
- Fig. 31 North America Humira market, 2018 2030 (USD Million)
- Fig. 32 U.S. country dynamics
- Fig. 33 U.S. Humira market, 2018 2030 (USD Million)
- Fig. 34 Canada country dynamics
- Fig. 35 Canada Humira market, 2018 2030 (USD Million)



- Fig. 36 Mexico country dynamics
- Fig. 37 Mexico Humira market, 2018 2030 (USD Million)
- Fig. 38 Europe Humira market, 2018 2030 (USD Million)
- Fig. 39 UK country dynamics
- Fig. 40 UK Humira market, 2018 2030 (USD Million)
- Fig. 41 Germany country dynamics
- Fig. 42 Germany Humira market, 2018 2030 (USD Million)
- Fig. 43 France country dynamics
- Fig. 44 France Humira market, 2018 2030 (USD Million)
- Fig. 45 Italy country dynamics
- Fig. 46 Italy Humira market, 2018 2030 (USD Million)
- Fig. 47 Spain country dynamics
- Fig. 48 Spain Humira market, 2018 2030 (USD Million)
- Fig. 49 Norway country dynamics
- Fig. 50 Norway Humira market, 2018 2030 (USD Million)
- Fig. 51 Sweden country dynamics
- Fig. 52 Sweden Humira market, 2018 2030 (USD Million)
- Fig. 53 Denmark country dynamics
- Fig. 54 Denmark Humira market, 2018 2030 (USD Million)
- Fig. 55 Asia Pacific Humira market, 2018 2030 (USD Million)
- Fig. 56 Japan country dynamics
- Fig. 57 Japan Humira market, 2018 2030 (USD Million)
- Fig. 58 China country dynamics
- Fig. 59 China Humira market, 2018 2030 (USD Million)
- Fig. 60 India country dynamics
- Fig. 61 India Humira market, 2018 2030 (USD Million)
- Fig. 62 Australia country dynamics
- Fig. 63 Australia Humira market, 2018 2030 (USD Million)
- Fig. 64 South Korea country dynamics
- Fig. 65 South Korea Humira market, 2018 2030 (USD Million)
- Fig. 66 Thailand country dynamics
- Fig. 67 Thailand Humira market, 2018 2030 (USD Million)
- Fig. 68 Latin America Humira market, 2018 2030 (USD Million)
- Fig. 69 Brazil country dynamics
- Fig. 70 Brazil Humira market, 2018 2030 (USD Million)
- Fig. 71 Argentina country dynamics
- Fig. 72 Argentina Humira market, 2018 2030 (USD Million)
- Fig. 73 MEA Humira market, 2018 2030 (USD Million)
- Fig. 74 South Africa country dynamics



- Fig. 75 South Africa Humira market, 2018 2030 (USD Million)
- Fig. 76 Saudi Arabia country dynamics
- Fig. 77 Saudi Arabia Humira market, 2018 2030 (USD Million)
- Fig. 78 UAE country dynamics
- Fig. 79 UAE Humira market, 2018 2030 (USD Million)
- Fig. 80 Kuwait country dynamics
- Fig. 81 Kuwait Humira market, 2018 2030 (USD Million)
- Fig. 82 Company categorization
- Fig. 83 Company market position analysis
- Fig. 84 Strategic framework



#### I would like to order

Product name: Humira Market Size, Share & Trends Analysis Report By Product (Branded, Biosimilar),

By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), By Distribution

Channel, By Region, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/H8B0C7734715EN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/H8B0C7734715EN.html">https://marketpublishers.com/r/H8B0C7734715EN.html</a>